CoChat

Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome

Open access

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). METHODS: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47 ± 18 with IBS diagnosed by Rome III criteria and with a score ≥ 150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as "placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes" or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). FINDINGS: Open-label placebo produced significantly higher mean (±SD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2 ± 1.0 vs. 4.0 ± 1.1, p<.001) and at 21-day endpoint (5.0 ± 1.5 vs. 3.9 ± 1.3, p = .002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p = .008 and p = .03) and adequate relief (IBS-AR, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p = .08). CONCLUSION: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent. TRIAL REGISTRATION: ClinicalTrials.gov NCT01010191.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0015591

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Enrollment Flowchart.
Figure 1 Enrollment Flowchart.CC0 · PubMed Central
Figure 2 Outcomes at the 21-Day Endpoint by Treatment Group.
Figure 2 Outcomes at the 21-Day Endpoint by Treatment Group.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. SJ Vanner, 2004, Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome and functional dyspepsia., Gut, 53, 666, 10.1136/gut.2003.021857 · DOI · Paper page

Cited by

See all 900

Metadata

Authors
Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Harvard University (US)
  • National Institutes of Health (US)
  • University of Hull (GB)
Corresponding author
Kaptchuk, Ted J.
Venue
PLoS ONE
Published
2010-12-22
Volume
5
Issue
12
Pages
e15591
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2105330971
Cited by
900
References
43
Citations by year
2026: 28 · 2025: 44 · 2024: 48 · 2023: 56 · 2022: 55 · 2021: 67 · 2020: 72 · 2019: 55 · 2018: 97 · 2017: 48 · 2016: 55 · 2015: 55 · 2014: 65 · 2013: 48 · 2012: 58
FWCI
29.43
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • Europe PMC (PubMed Central) (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • U.S. Department of Health and Human Services
  • Bernard Osher Foundation
  • National Institutes of Health (5r01at000402-04)
  • Japan Society for the Promotion of Science (13J11021)
  • National Center for Complementary and Alternative Medicine
  • National Center for Complementary and Integrative Health (R01AT004662, K24AT004095, R01 AT00402-01)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Complementary and alternative medicine › Acupuncture Treatment Research Studies
Keywords
irritable bowel syndrome, placebo effect, open-label placebo, symptom severity, quality of life, patient-provider interaction, informed consent
MeSH terms
Adult, Female, Humans, Deception, Male, Middle Aged, Placebos, Time Factors, Treatment Outcome, Patient Satisfaction, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome. https://app.cochat.ai/papers/10.1371/journal.pone.0015591
The paper
Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J. (2010). Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome. PLoS ONE. https://doi.org/10.1371/journal.pone.0015591

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.